{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:37:17Z","timestamp":1788971837576,"version":"build-2803163510"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,3,31]]},"DOI":"10.18632\/aging.202635","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T12:20:40Z","timestamp":1614860440000},"page":"8248-8275","source":"Crossref","is-referenced-by-count":13,"title":["Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2"],"prefix":"10.18632","volume":"13","author":[{"given":"Weihang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, China"},{"name":"Department of Orthopaedics, Daxing Hospital, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjing","family":"Zhao","sequence":"additional","affiliation":[{"name":"College of Clinical Medicine, Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxing","family":"Lu","sequence":"additional","affiliation":[{"name":"Hou Zonglian Medical Experimental Class, Xi'an Jiaotong University, Xi'an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","article-title":"JAK2 inhibitors for myeloproliferative neoplasms: what is next?","volume":"13","author":"Verstovsek","year":"2017","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.","volume":"9","author":"Vannucchi","year":"2018","journal-title":"Am J Hematol"},{"key":"4","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.","volume":"9","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-018-0109-0","article-title":"Myelofibrosis treatment algorithm 2018.","volume":"8","author":"Vannucchi","year":"2018","journal-title":"Blood Cancer J"},{"key":"6","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1038\/bcj.2017.6","article-title":"The role of the extracellular matrix in primary myelofibrosis.","volume":"7","author":"Ravid","year":"2017","journal-title":"Blood Cancer J"},{"key":"7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ajh.25053","article-title":"Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.","volume":"9","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"key":"8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbmt.2017.09.016","article-title":"Hematopoietic cell transplantation for myelofibrosis: the dynamic international prognostic scoring system plus risk predicts post-transplant outcomes.","volume":"2","author":"Sandmaier","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial.","volume":"1","author":"Kuliczkowski","year":"2015","journal-title":"JAMA Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/j.wneu.2019.05.264","article-title":"Computational study of novel natural inhibitors targeting O-methylguanine-DNA methyltransferase.","volume":"13","author":"Zhao","year":"2019","journal-title":"World Neurosurg"},{"key":"11","doi-asserted-by":"publisher","first-page":"e0216678","DOI":"10.1371\/journal.pone.0216678","article-title":"Computational study on new natural compound agonists of stimulator of interferon genes (STING).","volume":"1","author":"Jin","year":"2019","journal-title":"PLoS One"},{"key":"12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.steroids.2012.10.021","article-title":"Synthesis of 14',15'-dehydro-ritterazine Y via reductive and oxidative functionalizations of hecogenin acetate.","volume":"7","author":"Lee","year":"2013","journal-title":"Steroids"},{"key":"13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.steroids.2013.02.015","article-title":"Synthesis of C17-OH-north unit of Ritterazine G via \u201cRed-Ox\u201d modifications of Hecogenin acetate.","volume":"7","author":"Lee","year":"2013","journal-title":"Steroids"},{"key":"14","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.","volume":"2","author":"Antonioli","year":"2011","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"e17238","DOI":"10.1371\/journal.pone.0017238","article-title":"Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods.","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1755-8794-5-23","article-title":"Batch correction of microarray data substantially improves the identification of genes differentially expressed in rheumatoid arthritis and osteoarthritis.","volume":"5","author":"Kinne","year":"2012","journal-title":"BMC Med Genomics"},{"key":"17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1182\/blood-2016-06-721662","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"12","author":"Hasserjian","year":"2016","journal-title":"Blood"},{"key":"18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances.","volume":"3","author":"Tefferi","year":"2016","journal-title":"Blood Rev"},{"key":"19","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.","volume":"10","author":"Tefferi","year":"2005","journal-title":"Blood"},{"key":"20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International working group for myelofibrosis research and treatment (IWG-MRT).","volume":"3","author":"Deeg","year":"2007","journal-title":"Leuk Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia.","volume":"34","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia.","volume":"2","author":"Tefferi","year":"2005","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17474086.2018.1484280","article-title":"Diagnosis and management of prefibrotic myelofibrosis.","volume":"1","author":"Arcaini","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"24","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","volume":"12","author":"Rambaldi","year":"2014","journal-title":"Blood"},{"key":"25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical bayes methods.","volume":"8","author":"Rabinovic","year":"2007","journal-title":"Biostatistics"},{"key":"26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype.","volume":"2","author":"Pardanani","year":"2014","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"publisher","first-page":"9043","DOI":"10.18632\/aging.102372","article-title":"T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma.","volume":"1","author":"Chen","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10528-017-9794-9","article-title":"Novel biomarkers for non-functioning invasive pituitary adenomas were identified by using analysis of microRNAs expression profile.","volume":"5","author":"Zhang","year":"2017","journal-title":"Biochem Genet"},{"key":"29","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1126\/science.1071924","article-title":"TNF-R1 signaling: a beautiful pathway.","volume":"29","author":"Goeddel","year":"2002","journal-title":"Science"},{"key":"30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ejphar.2018.06.034","article-title":"Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets.","volume":"83","author":"Manna","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"31","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3390\/ijms21072275","article-title":"Vasculoprotective effects of vildagliptin. Focus on atherogenesis.","volume":"2","author":"Malinowski","year":"2020","journal-title":"Int J Mol Sci"},{"key":"32","doi-asserted-by":"publisher","first-page":"e1003368","DOI":"10.1371\/journal.pgen.1003368","article-title":"Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB.","volume":"9","author":"Prasanth","year":"2013","journal-title":"PLoS Genet"},{"key":"33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3346\/jkms.2001.16.4.424","article-title":"Expression of the G1-S modulators in hepatitis B virus-related hepatocellular carcinoma and dysplastic nodule: association of cyclin D1 and p53 proteins with the progression of hepatocellular carcinoma.","volume":"1","author":"Park","year":"2001","journal-title":"J Korean Med Sci"},{"key":"34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1478-3231.2011.02696.x","article-title":"Quantitative methylation analysis reveals gender and age differences in p16INK4a hypermethylation in hepatitis B virus-related hepatocellular carcinoma.","volume":"3","author":"Lu","year":"2012","journal-title":"Liver Int"},{"key":"35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.steroids.2012.05.002","article-title":"Application of hypoiodite-mediated aminyl radical cyclization to synthesis of solasodine acetate.","volume":"7","author":"Lee","year":"2012","journal-title":"Steroids"},{"key":"36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fphys.2016.00430","article-title":"Lipocalin 2 (LCN2) expression in hepatic malfunction and therapy.","volume":"7","author":"Weiskirchen","year":"2016","journal-title":"Front Physiol"},{"key":"37","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1158\/1078-0432.CCR-08-1136","article-title":"Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.","volume":"1","author":"Moses","year":"2008","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1006\/bbrc.1994.2096","article-title":"Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils.","volume":"20","author":"Kjeldsen","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"39","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1182\/blood-2013-12-544197","article-title":"miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155\/JARID2 axis in abnormal megakaryopoiesis.","volume":"12","author":"Bisognin","year":"2014","journal-title":"Blood"},{"key":"40","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2215\/CJN.09430913","article-title":"Urinary biomarkers and progression of AKI in patients with cirrhosis.","volume":"9","author":"Parikh","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"41","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.","volume":"4","author":"Ward","year":"2007","journal-title":"Mol Immunol"},{"key":"42","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.","volume":"12","author":"Busque","year":"2014","journal-title":"Blood"},{"key":"43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in Malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.","volume":"5","author":"Marubayashi","year":"2015","journal-title":"Cancer Discov"},{"key":"44","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs.","volume":"10","author":"O\u2019Shea","year":"2018","journal-title":"J Leukoc Biol"},{"key":"45","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","article-title":"Activation of JAK\/STAT signaling in megakaryocytes sustains myeloproliferation","volume":"2","author":"Levine","year":"2019","journal-title":"Clin Cancer Res"},{"key":"46","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.hoc.2012.07.008","article-title":"Therapy with JAK2 inhibitors for myeloproliferative neoplasms.","volume":"2","author":"Verstovsek","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"47","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/cea.13217","article-title":"The JAK1\/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.","volume":"4","author":"Dik","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"48","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1021\/ci6004299","article-title":"Validation studies of the site-directed docking program LibDock.","volume":"4","author":"LaLonde","year":"2007","journal-title":"J Chem Inf Model"},{"key":"49","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program.","volume":"3","author":"Cui","year":"2009","journal-title":"J Comput Chem"},{"key":"50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10822-014-9807-2","article-title":"Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity.","volume":"2","author":"Coumar","year":"2015","journal-title":"J Comput Aided Mol Des"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T16:25:13Z","timestamp":1617726313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,31]]}},"alternative-id":["202635","33686952"],"URL":"https:\/\/doi.org\/10.18632\/aging.202635","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]}}}